Therefore, these data, together with previous reports 35-38, further support the role of HMGA2 in ccRCC, and provide more experimental evidence and a theoretical basis for using HMGA2 as a therapeutic target in patients with ccRCC. This evidence concerns the gene HMGA2 and nonpapillary renal cell carcinoma.